GlassScriptPhysician profile
Richard Haddad
NPI 1750382800
$1,107,786.42
in general payments reported to CMS, 2019-2025
70 companies · $175K in 2025
The $175K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303K · 2020: $93K · 2021: $110K · 2022: $156K · 2023: $127K · 2024: $145K · 2025: $175K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $366K · Travel and Lodging: $33K · Food and Beverage: $29K · Consulting Fee: $19K · Education: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $366,043.50 |
| Travel and Lodging | $32,746.59 |
| Food and Beverage | $29,247.45 |
| Consulting Fee | $18,552.50 |
| Education | $412.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $229,531.27 | 2019-2025 | |
| Janssen Biotech, INC. | $149,233.28 | 2019-2025 | Tremfya, Simponi Aria |
| Horizon Therapeutics Plc | $122,975.21 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $92,661.16 | 2019-2025 | Benlysta |
| Celgene Corporation | $88,721.97 | 2019 | |
| Amgen INC. | $86,635.61 | 2019-2025 | Uplizna, Otezla, Otezla |
| Lilly USA, LLC | $78,246.05 | 2019-2024 | Taltz, Olumiant |
| Astrazeneca Pharmaceuticals LP | $44,059.22 | 2021-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $37,231.46 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $35,604.13 | 2019-2025 | |
| Pfizer INC. | $26,883.61 | 2019-2025 | |
| Genzyme Corporation | $25,748.66 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $20,834.77 | 2019 | |
| Ucb, INC. | $19,045.50 | 2019-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $11,397.81 | 2020-2025 | Acthar |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.